Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03122509 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03122509: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03122509 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03122509, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
Interventions
- DRUG durvalumab
- RADIATION Radiotherapy (RT)
- DRUG tremelimumab
- PROCEDURE ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2021-04-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03122509
The ClinicalTrials.gov registry entry for NCT03122509 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which durvalumab is the first listed.
NCT03122509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03122509 about?
NCT03122509 is a clinical study titled "A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer". The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.
What is the current status of trial NCT03122509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-04-24. Estimated completion is 2021-04-28.
What interventions are being tested in trial NCT03122509?
The interventions under investigation include: durvalumab (DRUG), Radiotherapy (RT) (RADIATION), tremelimumab (DRUG), ablation (PROCEDURE).
Who is sponsoring clinical trial NCT03122509?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.